Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

<p>Figure S8R</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Shiyi Yu (17079079) (author)
Бусад зохиолчид:	Ying Wang (17079082) (author), Xue Gong (17079085) (author), Zhehao Fan (17079088) (author), Zheng Wang (17079091) (author), Zhengyan Liang (17079094) (author), Rui Wu (17079097) (author), Binjie Cao (17079100) (author), Ning Wang (17079103) (author), Caili Bi (17079106) (author), Dan Lv (17079109) (author), Haibo Sun (17079112) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Cycle Signal transduction pathways Drug Resistance Regulation of gene expression in drug resistance Endocrine-Related Cancers
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S3 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S4 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
-н: Shiyi Yu (17079079)
Хэвлэсэн: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
-н: Ossia M. Eichhoff (14964145)
Хэвлэсэн: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
-н: Naoual Menssouri (16617248)
Хэвлэсэн: (2025)

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
-н: Laura E. Stevens (14961009)
Хэвлэсэн: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
-н: Marta J. Llorca-Cardenosa (14961612)
Хэвлэсэн: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
-н: Marta J. Llorca-Cardenosa (14961612)
Хэвлэсэн: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
-н: Marta J. Llorca-Cardenosa (14961612)
Хэвлэсэн: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
-н: Marta J. Llorca-Cardenosa (14961612)
Хэвлэсэн: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
-н: Marta J. Llorca-Cardenosa (14961612)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_blvokujftr4ptq27te88a3jv8k